A 21-Day, Randomized, Controlled Study to Evaluate the Skin Irritation Potential of BAY H006689, Naproxen 10% Topical Gel in Healthy Subjects Using a Cumulative Irritant Patch Test Design
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Bayer
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Skin sensitization potential measured by the mean and total cumulative irritancy score
研究概览
简要总结
Researchers are looking for a better way to treat muscle and joint pains. Researchers have seen that medicines which help reduce pain and inflammation could be safer when applied directly to the skin, called topical application, than when taken by mouth. However, recent studies have found that using these medications on the skin can sometimes cause skin reactions such as redness, itching, or irritation in the area where the medication is applied.
BAYH006689 topical gel is under development for the treatment of muscle and joint pains.
In this study, participants will be healthy and will not benefit from BAYH006689. However, the study will provide information about how to test BAYH006689 in future studies with people who have muscle and joint pain.
The main purpose of this study is to check whether BAYH006689 topical gel causes any irritation to the skin in healthy participants using a patch test called cumulative irritant patch test design. To do this, researchers will apply gel to participants' skin once a day for 21 days. Skin reactions will be assessed using a scale which will provide a score for redness, swelling, and other signs of skin irritation.
In this study, researchers will randomly assign 4 sites adjacent to each other, on the back of the participants' bodies just below the shoulder blades.
The following treatment gels will be applied using a patch.
- BAYH006689
- Placebo, which looks like the study drug, but does not have any medicine in it.
- 0.2% sodium lauryl sulfate (is a common ingredient in personal care products and when in contact with skin it could cause some skin irritation)
- 0.9% saline
Each participant will be in this study for 22 days, which includes:
- a visit to the clinic within 21 days of the study start, to confirm if the participant can take part in the study.
- participants will receive their assigned treatment gels at the identified skin site for 21 days.
- an end of study visit on Day 22, during which the researchers will remove the designed patches and assess any signs of skin irritation.
During the study, the doctors and their study team will:
- do physical examinations
- check participants' health by performing urine tests
- ask the participants questions about how they are feeling and what adverse events they are having An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
盲法说明
The treatments (IPs and control) will not be blinded to investigative personnel involved in the preparation/application and removal of treatments. However, the Investigator and trained evaluator involved in the evaluation of responses, will remain blinded during the course of the study until Database Lock and finalization of the Statistical Analysis Plan.
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adult
- •Is 18 years of age or older
- •Free of any systemic or dermatological disorder that may interfere with results or increase risk of adverse events (AEs)
排除标准
- •Has a condition and/or is using medications that may interfere with the study results
- •Pregnant or planning to get pregnant or breastfeeding
- •Is currently participating in any clinical testing
研究组 & 干预措施
BAYHO06689
Topical application of BAYH006689 naproxen 10% topical gel on the intact skin
干预措施: Naproxen (BAYH006689) (Drug)
Placebo
Topical application of placebo gel which contains 0% of naproxen on the intact skin
干预措施: Placebo Gel (Drug)
Negative control
Topical application of the sterile 0.9% saline (negative control) on the intact skin
干预措施: A solution of 0.9% Saline (Drug)
Positive control
Topical application of the 0.2% sodium lauryl sulfate (SLS) (positive control) on the intact skin
干预措施: A solution of 0.2% SLS (Drug)
结局指标
主要结局
Skin sensitization potential measured by the mean and total cumulative irritancy score
时间窗: 22 days
次要结局
未报告次要终点
